Previous studies have shown that loss of peroxisome proliferator-activated receptor alpha (PPARα) in the liver results in inflammation and hyperlipidemia in response to HFD (44, 45), and PPARα agonists are approved for the treatment of dyslipidemia (54). Here, PPARA is linked to metabolic syndrome.